SCHEMBL3851071

SCHEMBL3851071

COCCNc1nc(-c2ccc3[nH]c(NC(=O)c4cccs4)nc3c2)cc(=O)[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
KDM4E B2RXH2 4/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 2/20 0.51
MAPT P10636 4/20 0.42
ALDH1A1 P00352 4/20 0.42
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 2/20 0.42
ABL1 P00519 2/20 0.42
MAPK1 P28482 2/20 0.42
HTT P42858 2/20 0.42
TP53 P04637 2/20 0.42
NFKB1 P19838 2/20 0.42
GMNN O75496 1/20 0.42
TUBB4A P04350 1/20 0.42
CYP1A2 P05177 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14513948 0.93 KDM4E (0.51) SMN1; SMN2KDM4ENPC1RAB9AMAPT
SCHEMBL3844543 0.90 SMN1; SMN2 (0.54) SMN1; SMN2KDM4ENPC1RAB9AMAPT
SCHEMBL3846770 0.88 NPC1 (0.48) SMN1; SMN2KDM4ENPC1RAB9AMAPT
SCHEMBL3842312 0.85 KDM4E (0.50) SMN1; SMN2KDM4ENPC1RAB9AMAPT
SCHEMBL5633165 0.84 SMN1; SMN2 (0.46) SMN1; SMN2KDM4ENPC1RAB9AMAPT
SCHEMBL4369148 0.83 RAB9A (0.49) SMN1; SMN2KDM4ENPC1RAB9AMAPT
SCHEMBL3842878 0.83 KDM4E (0.49) SMN1; SMN2KDM4ENPC1RAB9AMAPT
SCHEMBL5633833 0.83 NPC1 (0.51) SMN1; SMN2KDM4ENPC1RAB9AMAPT
SCHEMBL14513963 0.82 KDM4E (0.54) SMN1; SMN2KDM4ENPC1RAB9AMAPT
SCHEMBL3842188 0.82 KDM4E (0.57) SMN1; SMN2KDM4ENPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713793-A4 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-09-02 EP claimed
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HASEGAWA MASAICHI 2007-05-24 US claimed
EP-1713793-A2 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS Smithkline Beecham Corporation (US) 2006-10-25 EP claimed
WO-2005076854-A2 PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117818-A1 Pyrimidinone compounds useful as kinase inhibitors HIPK3, HIPK1, HIPK2 SMN1; SMN2 1981/4885KDM4E 1975/4885NPC1 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.